Dr. Reddy's Laboratories Limited

DRREDDY

INE089A01031

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 03:52:10 2026-06-30 am EDT			5-day change	1st Jan Change
1,365.30 ^INR	-0.80%		+4.92%	+7.42%

Jun. 18	Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
Jun. 17	US progesterone supplies tighten as menopause treatment demand grows	RE

Health Care Down on Mixed Earnings -- Health Care Roundup

Published on 04/29/2026 at 05:40 pm EDT

Dow Jones

DR. REDDY'S LABORATORIES LIMITED

-0.80%

GE HEALTHCARE TECHNOLOGIES INC.

-1.08%

Health-care companies fell after mixed earnings.

Humana shares rallied even after the health insurer reported lower first-quarter profit as the company faced earnings headwinds from lower Medicare Advantage Star Ratings for 2026. Humana reiterated its earnings projection for the year.

GE HealthCare Technologies fell after the maker of imaging machines and other medical technology cut its profit outlook for the year after prices for memory chips, oil and freight jumped during the recent quarter.

The Canadian government authorized a generic version of Ozempic developed by Dr. Reddy's Laboratories, making it the first G7 country to approve a generic version of the massively popular GLP-1 diabetes treatment.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

04-29-26 1739ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
	DR. REDDY'S LABORATORIES LIMITED	1,365.30INR	-0.80%	+4.92%	12.12B
	GE HEALTHCARE TECHNOLOGIES INC.	65.05USD	-1.08%	+7.27%	29.59B

Latest news about Dr. Reddy's Laboratories Limited

Jun. 18	Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
Jun. 17	US progesterone supplies tighten as menopause treatment demand grows	RE
Jun. 16	Innoviva Specialty Therapeutics, Inc. Enters Distribution And Licensing Agreement With Dr. Reddy?s Laboratories Ltd. For XACDURO In Select International Markets	CI
Jun. 16	Innoviva' Specialty Therapeutics Unit Signs Licensing Deal With Dr. Reddy's for Xacduro	MT
Jun. 15	Global drugmakers invest billions to boost US presence	RE
Jun. 14	Indian shares join global rally on Gulf peace deal, oil slides	RE
Jun. 14	Indian shares set to join global rally on Gulf peace deal, oil slides	RE
Jun. 13	Dr. Reddy?s Laboratories Announces First-To-Market Launch Of Bosutinib Tablets 400Mg, A Generic Equivalent Of Bosulif, In The United States	CI
Jun. 08	Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	MT
Jun. 05	Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading	MT
Jun. 01	Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading	MT
Jun. 01	Caring Brands Inks Expanded Five-Year Licensing Deal With SanPellegrino Cosmetics	MT
May. 29	Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week	MT
May. 29	Inadvertently published alert on NYSE tagged to multiple companies withdrawn	RE
May. 27	Asian Equities Traded in US as ADRs Fall in Wednesday Trading	MT

Chart Dr. Reddy's Laboratories Limited

Duration

Period

DRREDDY: Dynamic Chart

Company Profile

Dr. Reddyâ€™s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Employees

27,527

Sector

Pharmaceuticals

Calendar

Jul. 10 - Ex-dividend date - 8 INR

More about the company